Similar articles for PMID: 30507954

Year	Number of Results
2003	1
2005	4
2006	2
2007	6
2008	2
2009	4
2010	10
2011	9
2012	10
2013	7
2014	10
2015	12
2016	7
2017	6
2018	11
2019	13
2020	15
2021	8
2022	8
2023	1
2024	0

1

Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.

Punzo F, Tortora C, Argenziano M, Casale M, Perrotta S, Rossi F. Punzo F, et al. PLoS One. 2018 Dec 3;13(12):e0208102. doi: 10.1371/journal.pone.0208102. eCollection 2018. PLoS One. 2018. PMID: 30507954 Free PMC article.

2

Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.

Shirley M, Plosker GL. Shirley M, et al. Drugs. 2014 Jun;74(9):1017-27. doi: 10.1007/s40265-014-0238-0. Drugs. 2014. PMID: 24919862 Review.

3

Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.

Taher AT, Temraz S, Cappellini MD. Taher AT, et al. Expert Rev Hematol. 2013 Oct;6(5):495-509. doi: 10.1586/17474086.2013.827411. Epub 2013 Oct 2. Expert Rev Hematol. 2013. PMID: 24083402 Review.

4

Effects of Iron Chelation in Osteosarcoma.

Argenziano M, Di Paola A, Tortora C, Di Pinto D, Pota E, Di Martino M, Perrotta S, Rossi F, Punzo F. Argenziano M, et al. Curr Cancer Drug Targets. 2021;21(5):443-455. doi: 10.2174/1568009620666201230090531. Curr Cancer Drug Targets. 2021. PMID: 33380300

5

Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.

Vlachodimitropoulou E, Chen YL, Garbowski M, Koonyosying P, Psaila B, Sola-Visner M, Cooper N, Hider R, Porter J. Vlachodimitropoulou E, et al. Blood. 2017 Oct 26;130(17):1923-1933. doi: 10.1182/blood-2016-10-740241. Epub 2017 Sep 1. Blood. 2017. PMID: 28864815 Free PMC article.

6

Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.

Shammo JM, Komrokji RS. Shammo JM, et al. Expert Rev Hematol. 2018 Jul;11(7):577-586. doi: 10.1080/17474086.2018.1486188. Epub 2018 Jun 19. Expert Rev Hematol. 2018. PMID: 29902097 Review.

7

Deferasirox for managing iron overload in people with thalassaemia.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D. Meerpohl JJ, et al. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007476. doi: 10.1002/14651858.CD007476.pub2. Cochrane Database Syst Rev. 2012. PMID: 22336831 Updated. Review.

8

Deferasirox.

Stumpf JL. Stumpf JL. Am J Health Syst Pharm. 2007 Mar 15;64(6):606-16. doi: 10.2146/ajhp060405. Am J Health Syst Pharm. 2007. PMID: 17353569 Review.

9

Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.

Huang L, Tian M, Liu Z, Liu C, Fu R. Huang L, et al. J Investig Med. 2022 Apr;70(4):953-962. doi: 10.1136/jim-2021-002147. Epub 2021 Dec 17. J Investig Med. 2022. PMID: 34921125

10

Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.

Pinto VM, Balocco M, Quintino S, Bacigalupo L, Gianesin B, Rizzi M, Malagò R, De Franceschi L, Forni GL. Pinto VM, et al. Am J Hematol. 2018 Oct;93(10):E338-E340. doi: 10.1002/ajh.25222. Epub 2018 Aug 14. Am J Hematol. 2018. PMID: 30033633 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

124 results

Results by year